Rohesh J. Fernando

Dr. Rohesh J. Fernando

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2016 in World Journal of Surgery
Verified
Journal Article
Open access
PDF file
MPMeghan Prin
Meghan Prin
TITakondwa Itaye
Takondwa Itaye
SCSarah Clark
Sarah Clark
RFRohesh J. Fernando
Rohesh J. Fernando
FNFelix Namboya
Felix Namboya
JSJulia Sobol
Julia Sobol
Background: The provision of critical care services is essential to healthcare systems and increasingly a global health focus, but many hospitals in sub‐Saharan Africa are unable to meet this need. Intensive care unit (ICU) mortality in this region is high, but studies describing the provision of critical care services are scarce.Methods: This was a retrospective cohort study of all patients admitted to the ICU at Queen Elizabeth Central Hospital (QECH) in Blantyre, Malawi, between September 1, 2013, and October 17, 2014. We summarized demographics, clinical characteristics, and outcomes, and analyzed factors associated with mortality.Results: Of 390 patients admitted to ICU during the study, 44.9 % of patients were male, and the median age was 22 years (IQR 6–35) years. Although most patients (73.1 %) were admitted with surgical diagnoses, the highest mortality was among patients admitted with sepsis (59.3 %), or obstetric (44.7 %) or medical (40.0 %) diagnoses. Overall ICU mortality was high (23.6 %).Conclusions: There is a shortage of data describing critical care in low‐resource settings, particularly in sub‐Saharan Africa. Surgical disease comprises the majority of ICU utilization in this study site, but medical and obstetric illness carried higher ICU mortality. These data may guide strategies for improving critical care in the region.

13 June 2022 in Journal of Clinical Monitoring and Computing
Verified
Journal Article
Open access
PDF file
AKAshish Khanna
Ashish Khanna
SMSteven Minear
Steven Minear
AKAndrea Kurz
Andrea Kurz
VMVanessa Moll
Vanessa Moll
KSKelly Stanton
Kelly Stanton
BBBev Ann Blackwell
Bev Ann Blackwell
Intra-abdominal hypertension (IAH) is frequently present in the critically ill and is associated with increased morbidity and mortality. Conventionally, intermittent ‘spot-check’ manual measurements of bladder pressure in those perceived as high risk are used as surrogates for intra-abdominal pressure (IAP). True patterns of IAH remain unknown. We explored the incidence of IAH in cardiac surgery patients and describe the intra-and postoperative course of IAP using a novel, high frequency, automated bladder pressure measurement system. Sub-analysis of a prospective, multicenter, observational study (NCT04669548) conducted in three large academic medical centers. Continuous urinary output (CUO) and IAP measurements were observed using the Accuryn Monitoring System (Potrero Medical, Hayward, CA). Data collected included demographics, hemodynamic support, and high-frequency IAP and CUO. One Hundred Thirty-Seven cardiac surgery patients were analyzed intraoperatively and followed 48 h postoperatively in the intensive care unit. Median age was 66.4 [58.3, 72.0] years, and 61% were men. Median Foley catheter dwell time was 56.0 [46.8, 77.5] hours, and median baseline IAP was 6.3 [4.0, 8.1] mmHg. 93% (128/137) of patients were in IAH grade I, 82% (113/137) in grade II, 39% (53/137) in grade III, and 5% (7/137) in grade IV for at least 12 cumulative hours. For maximum consecutive duration of IAH, 84% (115/137) of patients spent at least 12 h in grade I, 62% (85/137) in grade II, 18% (25/137) in grade III, and 2% (3/137) in grade IV IAH. During the first 48 h after cardiac surgery, IAH is common and persistent. Improved and automated monitoring of IAP will increase the detection of IAH—which normally would remain undetected using traditional intermittent monitoring methods.

1 December 2019 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
PDF file
LGLee A. Goeddel
Lee A. Goeddel
AHAmanda N. Hopkins
Amanda N. Hopkins
RFRohesh J. Fernando
Rohesh J. Fernando
INIván J. Núñez-Gil
Iván J. Núñez-Gil
HRHarish Ramakrishna
Harish Ramakrishna

1 March 2022 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
PDF file
ELEric Longfellow
Eric Longfellow
CACorinne Aberle
Corinne Aberle
JLJoseph Lamelas
Joseph Lamelas
MFMichael Fabbro
Michael Fabbro
EJEric Johnson
Eric Johnson
RFRohesh J. Fernando
Rohesh J. Fernando

4 October 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
EBElijah H. Beaty
Elijah H. Beaty
RFRohesh J. Fernando
Rohesh J. Fernando
MJMarie L. Jacobs
Marie L. Jacobs
GWGillian G. Winter
Gillian G. Winter
CBCatalina Bulla
Catalina Bulla
RRRoger L. Royster
Roger L. Royster
Background: Methohexital and propofol can both be used as sedation for direct current cardioversion (DCCV). However, there are limited data comparing these medications in this setting. We hypothesized that patients receiving methohexital for elective DCCV would be sedated more quickly, recover from sedation faster, and experience less adverse effects. Methods and Results: This was a prospective, blinded randomized controlled trial conducted at a single academic medical center. Eligible participants were randomly assigned to receive either methohexital (0.5 mg/kg) or propofol (0.8 mg/kg) as a bolus for elective DCCV. The times from bolus of the medication to achieving a Ramsay Sedation Scale score of 5 to 6, first shock, eyes opening on command, and when the patient could state their age and name were obtained. The need for additional medication dosing, airway intervention, vital signs, and medication side effects were also recorded. Seventy patients who were randomized to receive methohexital (n=37) or propofol (n=33) were included for analysis. The average doses of methohexital and propofol were 0.51 mg/kg and 0.84 mg/kg, respectively. There were no significant differences between methohexital and propofol in the time from end of injection to loss of conscious (1.4±1.8 versus 1.1±0.5 minutes; P =0.33) or the time to first shock (1.7±1.9 versus 1.4±0.5 minutes; P =0.31). Time intervals were significantly lower for methohexital compared with propofol in the time to eyes opening on command (5.1±2.5 versus 7.8±3.7 minutes; P =0.0005) as well as at the time to the ability to answer simple questions of age and name (6.0±2.6 versus 8.6±4.0 minutes; P =0.001). The methohexital group experienced less hypotension (8.1% versus 42.4%; P <0.001) and less hypoxemia (0.0% versus 15.2%; P =0.005), had lower need for jaw thrust/chin lift (16.2% versus 42.4%; P =0.015), and had less pain on injection compared with propofol using the visual analog scale (7.2±9.7 versus 22.4±28.1; P =0.003). Conclusions: In this model of fixed bolus dosing, methohexital was associated with faster recovery, more stable hemodynamics, and less hypoxemia after elective DCCV compared with propofol. It can be considered as a preferred agent for sedation for DCCV. Registration: URL: https://www.clinicaltrials.gov/ct ; Unique identifier: NCT04187196.

30 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ECETTORE CRIMI
ETTORE CRIMI
KRKaruna Rajkumar
Karuna Rajkumar
SCScott Coleman
Scott Coleman
RFRohesh J. Fernando
Rohesh J. Fernando
BMBryan Marchant
Bryan Marchant
AKAshish K Khanna
Ashish K Khanna
Background/Objectives: Mechanical circulatory support (MCS) is increasingly utilized for the management of acute decompensated heart failure (HF) and cardiogenic shock (CS). The primary goals of MCS are to restore systemic perfusion, reduce cardiac workload, and support end-organ function. A thorough understanding of cardiovascular physiology in patients supported by MCS is essential for clinical decision-making. This review summarizes current evidence on the physiological effects of various MCS devices, key monitoring techniques, patient management, and explores the emerging role of artificial intelligence (AI) in this field. Main Text: Short-term MCS devices include intra-aortic balloon pumps (IABP), percutaneous left-sided devices such as Impella (Abiomed, Danvers, MA, USA) and TandemHeart (LivaNova, London, UK), percutaneous right-sided support devices like Protek Duo (LivaNova, London, UK) and Impella RP Flex (Abiomed, Danvers, MA, USA), and veno-arterial extracorporeal membrane oxygenation (VA-ECMO). Long-term support is mainly provided by left ventricular assist devices (LVADs), including the HeartMate 3 (Abbott Laboratories, Chicago, IL, USA). Optimal MCS application requires an understanding of device-specific cardiovascular interactions and expertise in appropriate monitoring tools to assess device performance and patient response. The choice of device, timing of initiation, and patient selection must be individualized, with careful consideration of ethical implications. The integration of AI offers significant potential to advance clinical care by improving complication prediction, enabling real-time optimization of device settings, and refining patient selection criteria. Conclusions: MCS is a rapidly evolving field that requires a comprehensive understanding of cardiovascular interactions, careful selection of monitoring strategies, and individualized clinical management. Future research should address current device limitations, clarify device-specific clinical applications, and assess the validity of AI-driven technologies.